Iovance Biotherapeutics (IOVA) Stock Forecast & Price Target

Iovance Biotherapeutics is benefiting from accelerating commercial traction, with 2Q26 revenue of $99.3 million, up 66% year over year and 39% sequentially, and management raising FY26 revenue guidance to $410 million to $420 million on sustained AMTAGVI and Proleukin demand. The outlook is also supported by margin expansion, as gross margin rose to 56% from 41% in 1Q26, while the company ended the quarter with $303.7 million in cash and continued improving manufacturing scale through its expanded in-house iCTC facility. Beyond near-term sales, multiple catalysts across ESMO'26, 4Q26, and 2027—plus expanding authorized treatment centers to at least 110 by YE26 and broader ex-U.S. approvals—strengthen confidence in the platform’s long-term multi-indication growth potential.

Iovance Biotherapeutics is viewed negatively because lifileucel is assumed to fail to sustain the uptake seen in early 2026, cutting the probability of commercial success to 10% and implying very limited upside from its lead product. The investment case is further weakened by substantial clinical and regulatory risk, since the company’s assets may not show sufficient efficacy in ongoing or future trials and could face FDA or foreign approval delays that hinder commercialization. Competitive pressure from larger, better-resourced biotechnology and pharmaceutical peers, combined with heavy R&D spending and the likelihood that additional capital may eventually be needed, adds to the fundamental downside.